NutraLife Biosciences (NutraLife Biosciences) Debt-to-Equity : -1.35 (As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is NutraLife Biosciences Debt-to-Equity?

NutraLife Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $2.77 Mil. NutraLife Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.35 Mil. NutraLife Biosciences's Total Stockholders Equity for the quarter that ended in Sep. 2022 was $-2.32 Mil. NutraLife Biosciences's debt to equity for the quarter that ended in Sep. 2022 was -1.35.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for NutraLife Biosciences's Debt-to-Equity or its related term are showing as below:

NLBS's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.28
* Ranked among companies with meaningful Debt-to-Equity only.

NutraLife Biosciences Debt-to-Equity Historical Data

The historical data trend for NutraLife Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NutraLife Biosciences Debt-to-Equity Chart

NutraLife Biosciences Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-Equity

Get a 7-Day Free Trial

0.27

1.27

10.49

-4.41

NutraLife Biosciences Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Debt-to-Equity	Get a 7-Day Free Trial															-9.57	-4.41	-2.44	-1.73	-1.35

Competitive Comparison of NutraLife Biosciences's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, NutraLife Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NutraLife Biosciences's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NutraLife Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where NutraLife Biosciences's Debt-to-Equity falls into.

NutraLife Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

NutraLife Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.781	+	0.362)	/	-0.713
	=	-4.41

NutraLife Biosciences's Debt to Equity Ratio for the quarter that ended in Sep. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.767	+	0.352)	/	-2.315
	=	-1.35

NutraLife Biosciences (OTCPK:NLBS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

NutraLife Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of NutraLife Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NutraLife Biosciences (NutraLife Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NutraLife Biosciences Inc (OTCPK:NLBS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

6601 Lyons Road, Suite L-6, Coconut Creek, FL, USA, 33073

Website

https://www.nutralifebiosciences.com

NutraLife BioSciences Inc is engaged in the development, manufacturing and distribution of nutritional and dietary nutritional supplement products. The company is a branded and private label developer, manufacturer and distributor of a wide range of nutraceutical, wellness, and CBD products. It's private-label ingestible and skincare products include CBD-infused oral sprays, tinctures, pet drops, pain balms, and face creams. Its CBD products are derived from the seeds and mature stalks of the Cannabis Sativa plant which includes all parts and varieties of the cannabis sativa plant also known as hemp, which contain a tetrahydrocannabinol concentration.

Executives

Edgar Ward	director, 10 percent owner, officer: President and CEO	5851 HOLMBERG RD., UNIT 2511, PARKLAND FL 33067
Neil Catania	10 percent owner, officer: Vice President	5 FIREPLACE CT., EAST NORTHPORT NY 11731
Lee White	10 percent owner, other: 10% Shareholder	130 S. RD., PAGET D0 PG06